Harpoon Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $6.81
- Today's High:
- $7.4951
- Open Price:
- $7.37
- 52W Low:
- $5.44
- 52W High:
- $17.13
- Prev. Close:
- $7.41
- Volume:
- 35631
Company Statistics
- Market Cap.:
- $346.54 million
- Book Value:
- 0.079
- Revenue TTM:
- $46.51 million
- Operating Margin TTM:
- -79.86%
- Gross Profit TTM:
- $-49478000
- Profit Margin:
- -86.72%
- Return on Assets TTM:
- -26.97%
- Return on Equity TTM:
- -272.17%
Company Profile
Harpoon Therapeutics Inc had its IPO on 2019-02-08 under the ticker symbol HARP.
The company operates in the Healthcare sector and Biotechnology industry. Harpoon Therapeutics Inc has a staff strength of 46 employees.
Stock update
Shares of Harpoon Therapeutics Inc opened at $7.37 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $6.81 - $7.5, and closed at $6.81.
This is a -8.1% slip from the previous day's closing price.
A total volume of 35,631 shares were traded at the close of the day’s session.
In the last one week, shares of Harpoon Therapeutics Inc have slipped by -23.83%.
Harpoon Therapeutics Inc's Key Ratios
Harpoon Therapeutics Inc has a market cap of $346.54 million, indicating a price to book ratio of 1.4933 and a price to sales ratio of 0.7455.
In the last 12-months Harpoon Therapeutics Inc’s revenue was $46.51 million with a gross profit of $-49478000 and an EBITDA of $-34907000. The EBITDA ratio measures Harpoon Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Harpoon Therapeutics Inc’s operating margin was -79.86% while its return on assets stood at -26.97% with a return of equity of -272.17%.
In Q2, Harpoon Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 143.5%.
Harpoon Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-9.95 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Harpoon Therapeutics Inc’s profitability.
Harpoon Therapeutics Inc stock is trading at a EV to sales ratio of 0.5868 and a EV to EBITDA ratio of 0.4334. Its price to sales ratio in the trailing 12-months stood at 0.7455.
Harpoon Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $63.20 million
- Total Liabilities
- $25.33 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Harpoon Therapeutics Inc ended 2025 with $63.20 million in total assets and $0 in total liabilities. Its intangible assets were valued at $63.20 million while shareholder equity stood at $3.00 million.
Harpoon Therapeutics Inc ended 2025 with $0 in deferred long-term liabilities, $25.33 million in other current liabilities, 4000.00 in common stock, $-362801000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $32.80 million and cash and short-term investments were $45.56 million. The company’s total short-term debt was $2,875,000 while long-term debt stood at $0.
Harpoon Therapeutics Inc’s total current assets stands at $49.07 million while long-term investments were $0 and short-term investments were $12.76 million. Its net receivables were $0 compared to accounts payable of $3.63 million and inventory worth $0.
In 2025, Harpoon Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Harpoon Therapeutics Inc paid $0 in dividends in 2025.
Other key metrics
- Current Trading Price
- $6.81
- 52-Week High
- $17.13
- 52-Week Low
- $5.44
- Analyst Target Price
- $5.33
Harpoon Therapeutics Inc stock is currently trading at $6.81 per share. It touched a 52-week high of $17.13 and a 52-week low of $17.13. Analysts tracking the stock have a 12-month average target price of $5.33.
Its 50-day moving average was $8.15 and 200-day moving average was $7.76 The short ratio stood at 0.65 indicating a short percent outstanding of 0%.
Around 953.8% of the company’s stock are held by insiders while 5222.4% are held by institutions.
Frequently Asked Questions About Harpoon Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California.